Sequana Medical NV is a commercial-stage medical device company specializing in innovative treatments for drug-resistant fluid overload, a critical complication in patients with liver disease, heart failure, and cancer. This condition, affecting a growing patient population where standard diuretics fail, leads to excess fluid buildup—up to 15 liters—resulting in heightened mortality, frequent hospitalizations, severe pain, breathing difficulties, and mobility limitations. The company’s proprietary platforms include the alfa pump system, a fully implanted wireless device that automatically transfers abdominal fluid to the bladder for natural elimination, approved by the US FDA in December 2024 for recurrent or refractory ascites due to liver cirrhosis and holding CE mark in Europe. Over 1,000 alfa pump devices have been implanted globally, demonstrating clinical benefits and cost savings for healthcare systems. In development is Direct Sodium Removal (DSR) therapy, targeting systemic fluid overload, with promising early results from studies like MOJAVE. Founded in 2006 and headquartered in Ghent, Belgium, Sequana Medical NV operates in the healthcare sector with about 62 employees, focusing on expanding commercialization, particularly in the US liver transplant centers.